1.14
+0.02(+1.79%)
Currency In USD
Address
10355 Science Center Drive
Cambridge, MA 92121
United States of America
Phone
212 582 1199
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
August 29, 1991
| Name | Title | Pay | Year Born |
| Mr. Sanjeev Luther | Chief Executive Officer, President & Director | 625,000 | 1962 |
| Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior Vice President of Finance | 275,000 | 1967 |
| Ms. Dorothy J. Clarke | General Counsel | 0 | 1966 |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer | 0 | 1964 |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.